Arcutis Biotherapeutics (ARQT) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Arcutis Biotherapeutics published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Arcutis reports in thousands; figures here are converted to millions. Total revenues in Q3 2026 were all net product revenue. Other revenue (licensing payments) was nil in the quarter and in Q3 2025, but $2.0 million in Q4 2025, which is why Q4 2025 total revenues of $129.5 million exceed that quarter's $127.5 million of ZORYVE net product revenue.
• ZORYVE cream 0.05% was approved for atopic dermatitis in young children in October 2025 and had no sales in Q3 2025.

Source: Arcutis Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Arcutis Biotherapeutics splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Arcutis Biotherapeutics's ZORYVE cream 0.3% revenue was $37.8 million in Q3 2026, up 24% from $30.5 million in Q3 2025, 26% of total revenue.
• Arcutis Biotherapeutics's ZORYVE foam revenue was $75.1 million in Q3 2026, up 51% from $49.8 million in Q3 2025, 52% of total revenue.
• Arcutis Biotherapeutics's ZORYVE cream 0.15% revenue was $27.3 million in Q3 2026, up 44% from $18.9 million in Q3 2025, 19% of total revenue.
• Arcutis Biotherapeutics's ZORYVE cream 0.05% revenue was $3.7 million in Q3 2026, 3% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Arcutis gives one figure, full-year net product sales. In this release it raised its 2026 guidance to $535 million to $545 million, from $525 million to $540 million. The release prints the ranges with en dashes, so they are given here as a note.

Source: Arcutis Q3 2026 release, Nov 4, 2026.

Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the ARQT forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total revenues and GAAP diluted EPS, each as first reported in that quarter's release. Arcutis does not report an adjusted EPS.

We do not hold a confirmed date for Arcutis Biotherapeutics's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Arcutis Biotherapeutics sells one product family, ZORYVE (roflumilast), a PDE4 inhibitor in once-daily cream and foam formulations approved in the United States and Canada for plaque psoriasis, atopic dermatitis and seborrheic dermatitis. All of its $143.9 million of Q3 2026 revenue was net product revenue, against $99.2 million a year earlier, an increase of 45%. (Arcutis Q3 2026 release, Nov 4, 2026)

ZORYVE foam 0.3% is the largest product, with $75.1 million in the quarter against $49.8 million in Q3 2025. ZORYVE cream 0.3% brought in $37.8 million, ZORYVE cream 0.15% $27.3 million and ZORYVE cream 0.05%, which had no sales a year earlier, $3.7 million. (Arcutis Q3 2026 release, Nov 4, 2026; Arcutis Form 10-Q, Q3 2026, Nov 4, 2026)

Arcutis said the year-over-year increase and the 11% rise over Q2 2026 were predominantly due to increased unit demand, as well as modest improvements in gross-to-net (GTN) deductions, the rebates, chargebacks and fees deducted from gross sales to arrive at net product revenue. (Arcutis Q3 2026 release, Nov 4, 2026; Arcutis Form 10-K, 2025, Feb 25, 2026)

Arcutis sells through wholesalers and specialty pharmacies, and its sales are concentrated among them. In 2025 four customers each took more than 10% of gross product sales (17%, 12%, 11% and 11%), together 51%. Product revenue outside the United States was less than 10% of the total in 2025. (Arcutis Form 10-K, 2025, Feb 25, 2026)

Arcutis Biotherapeutics reports only GAAP results in its release, with no adjusted EPS. Net income was $8.8 million in Q3 2026, or $0.07 basic and $0.06 diluted per share, against $7.4 million, or $0.06 basic and diluted, in Q3 2025. (Arcutis Q3 2026 release, Nov 4, 2026)

Revenue grew faster than profit because spending rose too. Selling, general and administrative expenses were $99.6 million against $62.4 million a year earlier, which Arcutis attributed to marketing for its Skin to Believe In awareness campaign with Simone Biles and to personnel costs from a larger dermatology sales force and a new primary care and pediatric sales team. Research and development rose to $22.4 million from $19.6 million, mainly for ARQ-234 clinical work and medical affairs. (Arcutis Q3 2026 release, Nov 4, 2026)

Diluted weighted average shares were 136.8 million, against 132.9 million a year earlier. Stock-based compensation expense was $12.6 million in the quarter, and the income tax provision was $195 thousand. (Arcutis Q3 2026 release, Nov 4, 2026; Arcutis Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Arcutis Biotherapeutics guides one figure: full-year net product sales. With this release it raised its 2026 guidance to $535 million to $545 million, from $525 million to $540 million. Net product revenue for the first nine months was $379.2 million, so the range implies Q4 2026 net product sales of roughly $155.8 million to $165.8 million. (Arcutis Q3 2026 release, Nov 4, 2026)

The release lists the next dated events: an FDA target action date of February 23, 2027 for ZORYVE cream 0.05% in infants aged 3 to 24 months with atopic dermatitis, topline Phase 2 results for ZORYVE foam 0.3% in vitiligo by the end of 2026, and Phase 2 results in hidradenitis suppurativa in the first quarter of 2027. (Arcutis Q3 2026 release, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Arcutis Biotherapeutics, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Arcutis Biotherapeutics's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ARQT is on is ARQT a buy or a sell?, what analysts expect next is on the ARQT forecast, and what the company does is on the Arcutis Biotherapeutics (ARQT) stock page.

Every number on this page can be traced to a document Arcutis Biotherapeutics published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.